Edition:
United States

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

9.61USD
17 Aug 2018
Change (% chg)

$-0.12 (-1.23%)
Prev Close
$9.73
Open
$9.70
Day's High
$9.75
Day's Low
$9.37
Volume
111,130
Avg. Vol
237,413
52-wk High
$31.42
52-wk Low
$6.99

Chart for

About

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $403.87
Shares Outstanding(Mil.): 42.03
Dividend: --
Yield (%): --

Financials

  DERM.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -7.63 -- --
ROI: -59.34 3.33 12.67
ROE: -131.33 2.31 14.86

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.

Jun 29 2018

UPDATE 2-FDA approves Dermira's wipe for excessive armpit sweating

* Qbrexza expected to launch in October (Adds analyst comment, estimates; updates share move)

Jun 29 2018

Dermira's treatment for excessive armpit sweating gets U.S. approval

June 29 The U.S. Food and Drug Administration on Friday approved Dermira Inc's treatment for excessive armpit sweating, providing patients with an easy-to-use treatment option for an often embarrassing condition.

Jun 29 2018

BRIEF-Dermira Says Company's COO Position Was Eliminated

* DERMIRA SAYS COMPANY'S CHIEF OPERATING OFFICER POSITION WAS ELIMINATED, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source : https://bit.ly/2Iesp3E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 03 2018

BRIEF-Dermira Inc Q1 Loss Per Share $1.42

* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 03 2018

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

Mar 05 2018

UPDATE 2-Dermira to abandon acne drug, shares crater

* Drug results not to affect two other programs - company (Adds conference call details, analyst comment, updates share price)

Mar 05 2018

Dermira abandons acne drug

March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

Mar 05 2018

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

Mar 05 2018

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 22 2018

Competitors

Earnings vs. Estimates